Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Arthritis Research and Therapy Année : 2014

Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis

Résumé

Introduction: Regulatory T (Treg) cells play a crucial role in preventing autoimmune diseases and are an ideal target for the development of therapies designed to suppress inflammation in an antigen-specific manner. Type 1 regulatory T (Tr1) cells are defined by their capacity to produce high levels of interleukin 10 (IL-10), which contributes to their ability to suppress pathological immune responses in several settings. The aim of this study was to evaluate the therapeutic potential of collagen type II–specific Tr1 (Col-Treg) cells in two models of rheumatoid arthritis (RA) in mice. Methods: Col-Treg clones were isolated and expanded from collagen-specific TCR transgenic mice. Their cytokine secretion profile and phenotype characterization were studied. The therapeutic potential of Col-Treg cells was evaluated after adoptive transfer in collagen-antibody– and collagen-induced arthritis models. The in vivo suppressive mechanism of Col-Treg clones on effector T-cell proliferation was also investigated. Results: Col-Treg clones are characterized by their specific cytokine profile (IL-10highIL-4negIFN-γint) and mediate contact-independent immune suppression. They also share with natural Tregs high expression of GITR, CD39 and granzyme B. A single infusion of Col-Treg cells reduced the incidence and clinical symptoms of arthritis in both preventive and curative settings, with a significant impact on collagen type II antibodies. Importantly, injection of antigen-specific Tr1 cells decreased the proliferation of antigen-specific effector T cells in vivo significantly. Conclusions: Our results demonstrate the therapeutic potential of Col-Treg cells in two models of RA, providing evidence that Col-Treg could be an efficient cell-based therapy for RA patients whose disease is refractory to current treatments.

Domaines

Immunologie
Fichier principal
Vignette du fichier
Version publiée AR4567.pdf (2.22 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-02397296 , version 1 (06-12-2019)

Licence

Identifiants

Citer

Hélène Asnagli, Delphine Martire, Nathalie Belmonte, Julie Quentin, Hervé Bastian, et al.. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Research and Therapy, 2014, 16 (3), ⟨10.1186/ar4567⟩. ⟨hal-02397296⟩
388 Consultations
82 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More